Following are more highlights of company presentations fromthe 17th Annual Alex. Brown & Sons Health Care Seminar inBaltimore.
Amylin Pharmaceuticals Inc.
The San Diego company plans to file in the third quarter for itsfirst clinical trial, of AC 137 injectable amylin agonist as anadjunct to insulin treatment for type I diabetes.
Amylin (NASDAQ:AMLN) also plans to file later in 1993 fortrials of injectable amylin blockers for type II diabetes.The potential annual U.S. market for amylin as an adjunctto insulin is $300 million, and $1 billion for amylin blockersin type II diabetes, said Howard Greene Jr., chairman andchief executive officer. The stock gained 88 cents to $11.25.
Athena Neurosciences Inc.
The South San Francisco, Calif., company has filedinvestigational new drug applications with the FDA and theCanadian Health Protection Branch for AN-072 to treat cervicaldystonia, a condition that causes involuntary spasms in musclesof the neck and shoulder. Athena in January received U.S.orphan drug designation for the indication.
John Groom, president and CEO, said Athena expects to begin aPhase I trial in Canada this summer and, upon completion,begin a Phase II trial in the U.S. later this year. The company'sshares (NASDAQ:ATHN) were off 25 cents, closing at $8.75.
Cytel shares jumped $2 to $12.50 after the San Diego company(NASDAQ:CYTL) announced plans to enter the clinic withseveral monoclonal antibody products.
Trials of CY 727, a peptide blocker of MHC receptors on antigenpresenting cells associated with rheumatoid arthritis, will beginlate this year or early in 1993. The drug was developed incollaboration with Sandoz.
CY 1747 will begin clinicals in early 1993 as a treatment foracute inflammation and reperfusion injuries, such asmyocardial infarction or transplantation. Trials are expectedlater this year for CY 1787, and in the next 12 months for CY1503, also targeted at acute inflammation and reperfusioninjuries.
CY 1899, a vaccine for chronic hepatitis B, will begin its trialsbefore the end of the year.
The San Francisco, Calif., company expects to receive marketingapproval of its Factor VIII for hemophilia later this year, saidLouis Lavigne Jr., vice president and chief financial officer.
Genentech began in April human trials of nerve growth factoras a treatment for chemotherapy-associated peripheralneuropathies, he said. The stock (NYSE:GNE) closed at$26.63, down 50 cents.
Henri A. Termeer, president, CEO and chairman, said theCambridge, Mass., company's recombinant GCR is more thanhalfway through clinical trials to treat Gaucher's disease. Thecompany plans to file for U.S. marketing approval in the secondhalf of this year, he said. The drug is a recombinant form of theenzyme beta-glucocerebrosidase. The disease is a geneticdisorder caused by insufficient activity of the enzyme. Thestock (NASDAQ:GENZ) gained $2 to $46.25.
The Boulder, Colo., company plans to begin a one-year,extended Phase II trial of Antril interleukin-1 receptorantagonist as a treatment for rheumatoid arthritis later thisyear, said Jon Saxe, president and chief executive.
Synergen (NASDAQ:SYGN) also will file to begin trials of Antrilas a treatment for conjunctivitis in collaboration with InSiteVision Inc.
By August, the company will complete construction of a facilitythat will begin manufacturing 1,500 kilograms of Antril byyear end, sufficient to treat 160,000-320,000 patients annuallyfor sepsis syndrome, Saxe said. The company will file formarketing approval of Antril for sepsis in mid-1993.
Synergen's joint venture with Syntex to develop neurotrophicfactors is moving ahead, Saxe said. Phase I/II trials of ciliaryneurotrophic factor (CNTF) as a treatment for ALS (Lou Gehrig'sdisease) should begin next week, he said.
The stock closed unchanged at $41.25.
The Berkeley, Calif., company (NASDAQ:XOMA) plans to beginthis summer Phase I/II trials of CD5 Plus in juveniles withrheumatoid arthritis, said Steven C. Mendell, chairman. Thedrug, which targets T lymphocytes in autoimmune diseases andtransplant complications, is awaiting FDA approval as atreatment for graft-vs.-host disease. Mendell said Xomaremains confident of FDA approval of E5 to treat gram-negativesepsis. The company's shares rose $1.75 to $17.25.
(c) 1997 American Health Consultants. All rights reserved.